Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.
We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.
Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team consists of nine individuals who collectively have been involved in the development and approval of a significant number of anti-infective drugs.
Funding Rounds (4) - $69.33MUpdate
Current Team (2)Update
Board Members and Advisors (3)Update
|Sep 2, 2016||google.com - 0.0000|
|Apr 12, 2016||PRNewswire UK All - Antibacterial Drugs: World Industry and Market Prospects 2016-2026|
|Feb 9, 2016||PE HUB - Amplyx increases Series B funding to $49.2 mln and hires three|
|Jan 7, 2016||Xconomy - Former Cubist CEO Mike Bonney Joins Third Rock Ventures|
|Sep 17, 2015||Business Wire - Spero Expands Leadership Team, Advisory Board with Industry Veterans|
|Jun 30, 2015||SoCal - Tech - AnaptysBio Names Board Members|
|Jun 29, 2015||PRNewswire UK All - Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies|
|Jun 8, 2015||PRNewswire UK All - Antibacterial Drugs: World Industry and Market Prospects 2015-2025|
65 Hayden Avenue
Lexington, MA 02421